Antibe Therapeutics Inc.
ATE
Peringkat dalam Saham
#31911
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Harga Saham
$0.21483059
Terakhir disinkronkan: 2024-05-07
Kapitalisasi Pasar
$11.13M
Perubahan (1 hari)
0.34%
Perubahan (1 tahun)
-0.36%
Negara
CA
Perdagangan Antibe Therapeutics Inc. (ATE)
Kategori
Healthcare
EPS untuk Antibe Therapeutics Inc. (ATE)
EPS per 2026 TTM: 0
Menurut laporan keuangan terbaru dan harga saham Antibe Therapeutics Inc., EPS perusahaan saat ini (TTM) adalah 0. Pada akhir 2026, perusahaan memiliki EPS sebesar 0 sama dengan EPS tahun 2026 sebesar 0.
Riwayat EPS untuk Antibe Therapeutics Inc. dari 2026 hingga 2026
EPS di akhir setiap tahun
| Tahun | EPS | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
EPS untuk perusahaan sejenis atau pesaing
| Perusahaan | EPS | Perbedaan EPS | Negara |
|---|---|---|---|
| $3.11 | - |
US
|
|
| $3.59 | - |
IE
|
|
| $9.73 | - |
US
|
|
| $2.48 | - |
US
|
|
| - | - |
DE
|
